Hysan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hysan

Property Description
Active ingredient Xylometazoline hydrochloride
Form Nasal spray (aqueous solution)
Pharmacological class Alpha-adrenergic agonist, Sympathomimetic
Common use Relief of nasal congestion
Origin Synthetic compound

What is the Active Substance in Hysan?

Hysan is a medicinal preparation whose core component is the active ingredient Xylometazoline hydrochloride. This substance is chemically categorized as a synthetic compound belonging to the sympathomimetic class, specifically functioning as an alpha-adrenergic agonist. This pharmacological classification indicates that it acts directly on specific receptors found within the blood vessels, particularly those lining the nose. The compound's high affinity for these receptors makes it an effective local vasoconstrictor. Hysan is generally supplied as a single-active ingredient formulation.


Hysan: Form and Localized Decongestant Type

Hysan is classified as a topical decongestant intended for intranasal administration. It is typically supplied as an aqueous solution within a nasal spray container, commonly utilizing a metered-dose dispenser. This specific dosage form ensures that the Xylometazoline is delivered directly to the nasal mucosa—the area affected by congestion. This localized application provides a highly concentrated effect on the congested passages.


What is Hysan's General Purpose?

The general purpose of this medication is to provide rapid, symptomatic relief from nasal congestion and the sensation of obstruction. It achieves this by inducing local vasoconstriction, a physiological process that causes the blood vessels in the nasal tissues to narrow quickly. This action results in the effective shrinkage of the nasal mucosa, thereby clearing the airways and facilitating easier breathing. The product’s utility is focused on this immediate physical mechanism to resolve the primary physical symptom of a blocked nose.

Regulatory References

  1. NIH/NLM DailyMed Drug Label
  2. NIH/NLM: DailyMed Drug Label

What side effects are possible with Hysan?

Possible Side Effects and Safety Information

The adverse effects of Xylometazoline hydrochloride are officially categorized by the affected system-organ class and the frequency with which they are reported in clinical use, based on regulatory standards like the European Summary of Product Characteristics (SmPC) and FDA labeling.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Common (ge 1/100 to <1/10) Nasal dryness, nasal discomfort, application site burning/stinging, headache, nausea.
Uncommon (ge 1/1,000 to <1/100) Epistaxis (nosebleed), systemic allergic reactions, increased swelling of mucous membranes after discontinuation.
Rare (ge 1/10,000 to <1/1,000) Palpitations, tachycardia, hypertension.
Very Rare (<1/10,000) Hallucinations, convulsions, arrhythmias, apnoea (in infants/neonates).

Serious Safety Considerations

The primary duration-related safety pattern documented is rebound congestion (rhinitis medicamentosa), which is an increased swelling of the nasal mucous membranes associated with prolonged or excessive use after treatment stops. Regulatory documents note a potential for systemic vasoconstrictor effect and specify risks such as convulsions and apnoea in very young children.

Population-Specific Constraints

Caution is advised for patients with pre-existing conditions sensitive to sympathomimetic activity, including hypertension, cardiovascular disease, and diabetes mellitus. The medication is generally contraindicated in individuals with narrow-angle glaucoma or rhinitis sicca. Specific warnings are noted for use in pregnancy and for patients concurrently receiving Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

The official regulatory profile for Xylometazoline hydrochloride overdose highlights systemic and neurological manifestations that follow accidental ingestion or excessive use. The clinical picture is documented as consisting of phases of both central nervous system (CNS) stimulation, which may include convulsions and headache, and subsequent CNS inhibition, characterized by somnolence, dizziness, and ultimately coma.

Cardiovascular effects are central to the overdose documentation. Reported signs include irregularities such as bradycardia (slowed heart rate), tachycardia, and cardiac arrhythmias. Blood pressure may initially present as hypertension before transitioning to hypotension.

The most serious outcomes described in regulatory documents are respiratory depression, Cardiovascular (CV) collapse, and coma. The regulatory mandate is clear: seek immediate medical care if accidental ingestion occurs, as urgent symptomatic treatment under medical supervision is indicated.

Management protocols officially documented focus on supportive measures and may include the use of activated charcoal or gastric lavage in initial stages. Furthermore, a specific regulatory note emphasizes that small children are more sensitive to toxicity and prone to greater systemic absorption, which requires continuous monitoring of vital signs and ECG.

Therapeutic Uses of Hysan

What Hysan Treats: Main Uses and Benefits

Hysan is commonly used to provide supportive symptomatic relief across key domains where nasal symptoms interfere with daily functioning. Its primary role may be part of symptomatic management related to inflammatory or irritative states of the nasal passages.

The medication is applicable across conditions presenting with acute episodes and is relevant for easing symptom clusters that may become intense or disruptive. It is utilized to help manage the difficulty in breathing associated with the common cold, episodic allergic rhinitis (hay fever), and the obstruction related to sinusitis.

Immediate Symptom Support

This medication is applied when symptoms create noticeable physiological strain, offering symptomatic relief that helps patients cope more steadily with difficult episodes by supporting comfortable airflow.

“It helps address symptoms of increased discomfort, particularly when the nasal obstruction interferes with essential daily functions like sleeping.”

Hysan is commonly used when short-term symptomatic assistance is needed, providing supportive relief when severe nasal obstruction interferes with routine activities. Its primary therapeutic benefit is to contribute to improved comfort during periods of heightened symptoms, which may assist with maintaining functional stability.


Quick Fact: Relief for Nasal Blockage Hysan is commonly used for managing symptoms related to nasal obstruction, applied during phases where the patient experiences heightened discomfort.

Regulatory References

  1. NIH DailyMed Drug Label Information for Xylometazoline

Eligibility and Restrictions for Use

Who Can and Cannot Use Hysan? (Official Regulatory Information)

Eligibility for Xylometazoline hydrochloride (Hysan) is strictly defined by age, specific health conditions, and current treatments, as documented in official regulatory labels.

Contraindicated Populations (Absolute Non-Eligibility)

Use is contraindicated (must not be used) for individuals with a known hypersensitivity to the medicine, narrow-angle glaucoma, Rhinitis sicca or Atrophic rhinitis, a history of trans-sphenoidal hypophysectomy, or those currently using or having used Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Age-Related Eligibility

The medicine is contraindicated for children under 2 years of age for all concentrations. The higher concentration (e.g., 0.1% w/v) is contraindicated for children under 12 years. Lower concentrations (e.g., 0.05% w/v) are approved for use in children aged 2 to 11 years.

Restricted Use and Conditional Caution

Use requires caution in patients with pre-existing conditions sensitive to sympathomimetic agents. These include hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, and Long QT syndrome. Regarding reproductive status, use during pregnancy is not recommended, and caution is advised during breastfeeding.

What should I know about interactions with other medicines?

The official interaction profile for Xylometazoline hydrochloride, the active ingredient in Hysan, is primarily defined by its pharmacodynamic effects as a sympathomimetic agent, rather than metabolic interactions. As a topical nasal spray, systemic pharmacokinetic interactions are generally not documented in regulatory information.

Interaction scope

Property Value
Medicinal product categories with documented interactions: Monoamine Oxidase Inhibitors (MAOIs), Tri- and Tetra-cyclic Antidepressants, Antihypertensives, Cardiac Glycosides, Ergot Alkaloids.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic synergism resulting in intensified sympathomimetic effects. Antagonism leading to reduced hypotensive effect.
Timing-based interaction rules (if applicable): 14-day rule: Must not be co-administered if MAOIs have been taken within the preceding 14 days.

Resulting Interaction Structure

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formally contraindicated combination due to the severe cardiovascular risk, including a hypertensive crisis. Combining the drug with tri- and tetra-cyclic antidepressants may lead to an increase in blood pressure because of additive sympathomimetic effects. Xylometazoline may also reduce the efficacy of co-administered antihypertensives. Furthermore, regulatory information includes a specific interaction caution for Patients with Long QT Syndrome, noting a potential increased risk of serious ventricular arrhythmias.

Mechanism of Action

Hysan, in its industrial biocide application, contains a stabilized chlorine dioxide source that generates the chlorine dioxide (ClO2) radical in situ. ClO2 acts as a non-specific oxidizing agent targeting microbial tissues.

The primary biological targets are vital cellular components within the cell walls, cell membranes, and cytoplasm of microorganisms, including bacteria and fungi. The interaction is one of chemical oxidation, leading to the disruption of disulfide bonds in structural and functional proteins. ClO2 also reacts with amino acids, and RNA within the cell.

This molecular and intracellular pathway results in the denaturation of essential proteins and the disruption of the cell's integrity. Downstream, this causes the irreversible disruption of cell metabolism and the lysis of the microbial cell wall. The system-level physiological consequence of this oxidation cascade is the destruction of microbial populations.

Dosage and Administration Information

Administration of Hysan

Hysan nasal spray is designed for intranasal application. The device consists of a bottle equipped with a specialized pump system intended to deliver a precise volume of solution with each spray. Proper handling of the bottle is necessary to ensure the mechanical function of the spray head.

Preparation of the Bottle

Before the first application, or if the spray has not been used for an extended period, the pump mechanism may require priming. This involves removing the protective cap and depressing the pump several times into the air until a fine, uniform mist is released.

Application Technique

To facilitate the distribution of the solution within the nasal cavity, the following steps are typically observed:

  • Clear the nasal passages gently before use.
  • Remove the protective dust cap from the nozzle.
  • Hold the bottle with the nozzle pointing upward. The base of the bottle is usually supported by the thumb, while the index and middle fingers are placed on the finger rests of the nozzle.
  • Insert the nozzle tip slightly into one nostril.
  • Depress the pump mechanism once while breathing in gently through the nose.
  • Repeat the process for the other nostril if necessary.

After each use, the nozzle should be wiped clean with a dry, lint-free tissue to maintain hygiene, and the protective cap should be replaced securely to prevent contamination or clogging of the spray tip.

Storage and Handling

The container is designed to protect the solution from environmental contaminants. It is important to avoid tilting the bottle horizontally or downward during the actual spraying process to ensure the internal dip tube can effectively draw the liquid into the pump mechanism. To maintain the integrity of the solution, the spray should be used by only one individual to prevent the potential spread of pathogens.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hysan

This section provides a factual summary of the clinical research conducted on Xylometazoline, focusing on the types of studies performed, the outcomes researchers measured, and the known limits of the evidence, without offering medical advice.


Evidence for Nasal Congestion Related to the Common Cold

Research was studied for outcomes related to systemic or functional imbalance associated with the common cold. Studies conducted during periods of increased symptom activity have largely involved short-term Randomized Controlled Trials (RCTs), many of which was evaluated in adult patients presenting with cold symptoms. The studies research examined various outcomes, including objective measurements of nasal airflow and patient-reported outcomes describing perceived discomfort. The findings describe patterns where measurements related to objective airflow and subjective congestion scores were taken shortly after administration.


Research for Allergic Rhinitis Symptoms

Research was studied for the outcomes related to physical discomfort associated with conditions characterized by fluctuating or episodic manifestations, such as allergic rhinitis (hay fever). Trials for this indication have included RCTs that research examined the medication alongside placebo or other rhinitis therapies. Some research describes patterns where the medication was observed in settings evaluating short-term symptom changes when applied in studies examining patient-reported experiences during heightened periods of allergy symptoms.


What Remains Uncertain and Research Gaps

Scientific reviews and aggregated data highlight several key limitations and areas where research remains insufficient. Most controlled clinical trials have follow-up durations that were limited, meaning long-term effects are not fully established for treatment periods exceeding 7 to 10 days. Furthermore, evidence quality varies across studies, especially for subjective outcomes, where data for certain groups remain insufficient (such as older adults or those with specific comorbidities). The existing research provides limited information for long-term outcomes across all studied indications.

Frequently Asked Questions (FAQ)

Common questions about Hysan (FAQ)


Q: Does Hysan have any known long-term side effects?

Official information from regulatory bodies emphasizes that prolonged or excessive use may cause rebound nasal congestion (rhinitis medicamentosa). This condition is described as an increased swelling of the nasal mucous membranes that can happen after stopping treatment. Regulatory documents generally describe that the product is intended for short-term use, often advising against using the medication for more than seven consecutive days.


Q: How quickly should I expect Hysan to start working?

According to the official product information, the decongestant effect of Hysan is described as rapid. The onset of action typically begins within a few minutes of administration, with effects that may be sustained for up to 10 hours.


Q: What patient expectations are set regarding the time it takes to see results from Hysan?

The medication is intended to provide rapid, symptomatic relief from nasal congestion. The expected result is the shrinkage of the nasal mucosa (the lining of the nose) to facilitate easier breathing, which occurs shortly after the spray is used.


Q: What is the potential impact of Hysan on liver function?

Official side effect profiles, based on clinical experience, do not commonly or rarely list specific impacts on liver function (hepatotoxicity) in the frequency-classified adverse reactions sections. General regulatory cautions exist regarding the use of sympathomimetic agents in individuals with certain pre-existing conditions.


Q: Does taking Hysan require any specific lab tests or monitoring?

Regulatory documents do not mandate routine laboratory monitoring for the general user of this topical medication. However, caution is required for individuals with pre-existing conditions like hypertension (high blood pressure) or cardiovascular disease, which indicates that monitoring of these conditions may be relevant during use.


Q: Is Hysan often used with other medications?

Regulatory information primarily focuses on contraindicated or cautioned combinations, such as with MAOIs and certain antidepressants, due to the risk of serious interactions. The official profile does not typically document interactions with most non-sympathomimetic or non-cardiovascular medications.


Q: Is Hysan available without a prescription?

In many regions, regulatory classifications describe the active ingredient, Xylometazoline hydrochloride, as an Over-The-Counter (OTC) or General Sales List (GSL) product. This classification means it is widely available for non-prescription purchase.


Q: Can Hysan cause drowsiness or affect alertness?

Although the product is for local nasal use, some official documents note drowsiness, dizziness, and trouble sleeping as possible, systemic effects from absorption. These types of effects are typically listed as very rare in official adverse reaction classifications.


Q: Are there any common foods or supplements that interact with Hysan?

The official interaction profile exclusively lists drug-drug interactions, primarily with certain prescription medications like MAOIs and antidepressants. Regulatory documentation does not specifically document known interactions between this topical product and common foods or dietary supplements.


Q: What happens if I stop using Hysan suddenly?

An uncommon outcome associated with stopping Hysan is increased swelling of the nasal mucous membranes (rebound congestion). Users are advised that the use of the spray should be stopped if symptoms persist or worsen after the recommended short duration of treatment.


Q: Is there a generic version of Hysan available?

The active substance in Hysan is Xylometazoline hydrochloride, which is a widely available compound. Regulatory databases indicate this substance is the active ingredient in multiple commercially available products from various packagers, often marketed under non-proprietary names.


Q: Is Hysan used for pain relief?

The sole authorized use for this medication, as defined by regulatory indications, is for the symptomatic relief of nasal congestion. Official documentation does not indicate its use for pain relief.


Q: What does the research say about Hysan's effectiveness?

Regulatory reviews describe Xylometazoline as a medication with a documented profile for safety and for providing symptomatic relief of nasal congestion. The mechanism of action, which involves local vasoconstriction, is confirmed to effectively lead to a decrease in nasal blood flow and reduced swelling.


Q: Are there any common skin reactions linked to Hysan?

Official adverse reaction lists include hypersensitivity reactions (such as rash or pruritus, which is intense itching) under the Very Rare frequency classification. The appearance of a rash or pruritus is a reaction that should be discussed with a healthcare professional.


Q: Does Hysan affect blood pressure?

The medication should be used with caution in patients who already have hypertension (high blood pressure). In the general population, official documents list the occurrence of hypertension as a Rare adverse reaction, meaning it is not a common side effect.


Q: Is it normal to feel a bit nauseous when starting Hysan?

Nausea is listed as a Common side effect in official regulatory documents. This means that, based on clinical data, it is one of the more frequently reported effects and may occur in up to 1 in 100 people using the product.


Q: Can Hysan be used for symptoms other than its main approved use?

The regulatory label strictly defines the approved indications for this product. The medication is only approved for the symptomatic treatment of nasal congestion and runny nose in connection with common colds.


Q: Is Hysan considered a controlled substance?

In the United States, official regulatory records indicate that Xylometazoline hydrochloride is not listed on the DEA Controlled Substances Schedule. Its status in other international regions may be subject to different local scheduling rules regarding pharmacy access.


Q: Why does Hysan sometimes cause insomnia?

Sleep disturbances, including difficulty in sleeping or restlessness, are listed as Very Rare systemic side effects in official documents. This type of effect is related to the medication's stimulating properties on the nervous system.


Q: Do people develop a tolerance to Hysan over time?

Official documentation does not explicitly use the term 'tolerance,' but it does note that a reduced response to the spray is possible, especially when used frequently or for many days. This pattern is often associated with the risk of rebound nasal congestion.


Q: How is Hysan different from other similar treatments I see advertised?

Hysan contains the active substance Xylometazoline hydrochloride, which is classified as an alpha-adrenergic agonist. It is distinguished by its function as a topical vasoconstrictor that acts directly on the blood vessels in the nasal passages, unlike oral decongestants or nasal steroid sprays.


Q: Are there different strengths or forms of Hysan available?

Official information confirms that the product is commonly supplied as a nasal spray or nasal drops. These typically come in different concentrations, such as 0.05% w/v (often for children) and 0.1% w/v (often for adults and older children).


Q: Does Hysan contain gluten or common allergens?

Regulatory labels contain a list of the inactive ingredients (excipients), and these must be reviewed for specific allergens. Regulatory bodies require manufacturers to declare ingredients that may contain common allergens or gluten above certain thresholds.


Q: What kind of studies support the use of Hysan?

The evidence supporting the authorized use of Hysan primarily comes from short-term, randomized controlled trials (RCTs). These studies compare the medication to placebo or other treatments for acute nasal congestion and measure both objective airflow and patient-reported outcomes.


Q: Does Hysan affect fertility?

Official product information notes that no specific studies on foetal toxicity or fertility have been carried out in animals for Xylometazoline. Therefore, information on the effect on human fertility is limited in the current regulatory documents.


Q: What happens if I miss a use of Hysan?

The general regulatory instruction is to use the missed dose as soon as remembered or to skip it if it is almost time for the next scheduled dose. Regulatory guidance notes that users should not use extra medicine to compensate for a forgotten use.


Q: Are there reports of Hysan interacting with herbal supplements?

The official interaction profile does not specifically document or list known interactions with herbal supplements. Regulatory caution generally focuses on co-administered medicinal products, especially those that could intensify the drug's sympathomimetic effects.


Q: How common are serious side effects with Hysan?

Serious systemic effects, such as arrhythmias (irregular heartbeat), hypertension, and convulsions, are listed under the Rare (ge 1/10,000 to <1/1,000) or Very Rare (<1/10,000) frequency classifications in official documents. This indicates they are not commonly reported in users.


Q: Do people typically have to use Hysan forever?

Official regulatory guidance advises that the product is intended only for short-term, symptomatic relief. It is recommended that users do not use the product for more than seven consecutive days unless otherwise advised, due to the risk of developing rebound congestion.


Q: Is Hysan a preventative medicine?

Hysan is officially indicated for symptomatic relief of existing nasal congestion. Official documents do not describe the medication as a preventative medicine intended to stop symptoms from occurring.


Q: Why do official documents mention certain populations cannot use Hysan?

Contraindications are based on documented medical risks. For example, the medication’s sympathomimetic action on the cardiovascular system is the basis for caution in patients with hypertension or cardiovascular disease and contraindication for co-use with MAOIs (a type of antidepressant).


How should Hysan be stored and disposed of?

How to Store and Dispose of Hysan

Official regulatory documents define specific conditions for storing and disposing of Hysan nasal spray.

Storage Requirements

  • Temperature: The medicine must be stored at a temperature not exceeding 25°C (77°F).
  • Child Safety: It must be kept out of the sight and reach of children.
  • In-Use Stability: After the first opening, the nasal spray should not be used for longer than 6 months.
  • Container Care: After each use, the nasal adapter should be wiped and the protective cap replaced to maintain hygiene.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. The medicine should not be thrown into household waste or wastewater to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hysan found in:

A-Z Index: